WVE - ウェ―ブ・ライフ・サイエンシズ （WAVE Life Sciences Ltd.） ウェ―ブ・ライフ・サイエンシズWVEのチャート
WVEの企業情報
| symbol | WVE |
|---|---|
| 会社名 | Wave Life Sciences Ltd （ウェ―ブ・ライフ・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ウェーブ・ライフ・サイエンス（WAVE Life Sciences Ltd.）は遺伝子医薬品会社である。同社は合成化学薬品開発プラットフォームを通じて遺伝的定義された疾患向けの核酸治療候補製品パイプラインを設計、開発と商業化する。同社は疾患を促進するタンパク質の発現または機能不全の変異体タンパク質の産生を機能性タンパク質の産生に変換するために遺伝的欠陥を標的とするオリゴヌクレオチドを開発する。同社は核酸治療薬stereopureを開発する。stereopureオリゴヌクレオチドは各連結部に3次元配向で配置された原子を有する分子を含む。同社はハンチントン病（HD）とデュシェンヌ型筋ジストロフィー（DMD）にある3つのプログラムと3つの追加的開発候補製品を有する。 ウェ―ブ・ライフ・サイエンシズはシンガポ―ルのバイオ医薬品企業。臨床の前段階の研究に従事し、主に核酸医薬に焦点を当て根治が難しい病気に対する治療を目指す。遺伝子治療において、難病を進行させるタンパク質の発現を減らす方法、または機能不全の変異体タンパク質を機能的なタンパク質に変える方法などを研究・開発する。 Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. |
| 本社所在地 | 7 Straits View #12-00 Marina One East Tower 018936 SGP |
| 代表者氏名 | Gregory L. Verdine グレゴリー・L・ヴェルディネ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | -620784 |
| 設立年月日 | 41091 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 168人 |
| url | www.wavelifesciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/wve |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -126.02700 |
| 終値（lastsale） | 42.98 |
| 時価総額（marketcap） | 1260271035.66 |
| 時価総額 | 時価総額（百万ドル） 1300.736 |
| 売上高 | 売上高（百万ドル） 8.65300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 167.179 |
| 当期純利益 | 当期純利益（百万ドル） -127.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Wave Life Sciences Ltd revenues increased from $1.5M to $6.3M. Net loss increased 56% to $71.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 82% to $61.7M (expense) General and administrative increase of 35% to $16.9M (expense). |
WVEのテクニカル分析
WVEのニュース
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023 2023/04/26 12:30:00 GlobeNewswire
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company’s first quarter 2023 financial results and provide business updates.
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry 2023/04/20 12:30:00 GlobeNewswire
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats
Wave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Up 32.0% in March 2023/04/17 09:40:43 The AM Reporter
Wave Life Sciences Ltd. (NASDAQ:WVE – Get Rating) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 2,020,000 shares, a growth of 32.0% from the March 15th total of 1,530,000 shares. Based on an average trading volume of 428,200 shares, the short-interest ratio is presently 4.7 […]
Looking Into WAVE Life Sciences''s Return On Capital Employed 2023/03/23 14:46:02 Benzinga
Benzinga Pro data, WAVE Life Sciences (NASDAQ: WVE ) reported Q4 sales of $1.24 million. Earnings fell to a loss of $43.71 million, resulting in a 12.06% decrease from last quarter. WAVE Life Sciences collected $285 thousand in revenue during Q3, but reported earnings showed a $39.00 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests … Full story available on Benzinga.com
Wave Life Sciences Ltd. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:WVE) 2023/03/22 13:21:50 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023 2023/03/02 13:30:00 GlobeNewswire
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference 2023/02/09 21:05:00 GlobeNewswire
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.
What To Expect As Wave Life Sciences Ltd. (NASDAQ: WVE) Delivers An 27.27% Gain In 6 Months 2023/01/21 16:30:00 Marketing Sentinel
During the last session, Wave Life Sciences Ltd. (NASDAQ:WVE)’s traded shares were 0.68 million, with the beta value of the company hitting -0.90. At the end of the trading day, the stock’s price was $4.76, reflecting an intraday gain of 6.73% or $0.3. The 52-week high for the WVE share is $7.12, that puts it … What To Expect As Wave Life Sciences Ltd. (NASDAQ: WVE) Delivers An 27.27% Gain In 6 Months Read More »
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth Considering 2023/01/14 13:00:00 Stocks Register
Wave Life Sciences Ltd. (NASDAQ:WVE) price on Friday, January 13, rose 4.00% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.46. A look at the stock’s price movement, the close in the last trading session was $5.25, moving within a range at $5.13 and $5.695. The beta … Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Could Be Worth Considering Read More »
How should investors view Wave Life Sciences Ltd. (WVE)? 2023/01/13 15:00:00 US Post News
Wave Life Sciences Ltd. (NASDAQ:WVE) marked $5.25 per share on Thursday, down from a previous closing price of $5.26. While Wave Life Sciences Ltd. has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 93.73%, with highs and lows ranging from […]
Have you been able to find a good deal on Wave Life Sciences Ltd.’s shares? 2022/11/24 17:24:00 US Post News
As of Wednesday, Wave Life Sciences Ltd.’s (NASDAQ:WVE) stock closed at $4.21, up from $4.10 the previous day. While Wave Life Sciences Ltd. has overperformed by 2.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE rose by 6.05%, with highs and lows ranging from $5.31 […]
Investing in Wave Life Sciences Ltd. (WVE) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/14 16:40:00 US Post News
The share price of Wave Life Sciences Ltd. (NASDAQ:WVE) fell to $3.64 per share on Friday from $4.17. While Wave Life Sciences Ltd. has underperformed by -12.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, WVE fell by -23.21%, with highs and lows ranging from $5.31 […]
Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript 2022/11/10 19:55:23 Seeking Alpha
Wave Life Sciences Ltd. (NASDAQ:NASDAQ:WVE) Q3 2022 Earnings Conference Call November 10, 2022 08:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President…
Wave Life Sciences Ltd. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:WVE) 2022/11/10 18:26:37 Seeking Alpha
The following slide deck was published by Wave Life Sciences Ltd.
Wave Life Sciences: Q3 Earnings Snapshot 2022/11/10 13:30:42 One News Page
SINGAPORE (AP) _ Wave Life Sciences Pte. Ltd. (WVE) on Thursday reported a loss of $39 million in its third quarter. The Singapore-based company said it had a loss of 42 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks …